SecBot SecBot
8-K ·Filed Jun 15, 2026

SYRE

Spyre Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001636282-26-000083
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The strong efficacy and clean safety profile de-risk SPY002 as a potential best-in-class anti-TL1A. Watch for Part B randomized placebo-controlled data and SPY003 readout in Q3 2026, which could further validate the platform. The stock may re-rate upward on this catalyst, but given the open-label design and small sample (n=48), some skepticism may persist until confirmatory data.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$83.58
T+0 close · Jun 15, 2026 · via day close
Latest settled
+4.01%
T+60 · $86.93
Vs SPY
+3.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $83.58entry
  2. T+1 · 5mo ago −0.20%α +0.39% · $83.41
  3. T+5 · 5mo ago +20.03%α +21.41% · $100.32
  4. T+20 · 4mo ago +12.14%α +12.89% · $93.73
  5. T+60 · 2mo ago +4.01%α +3.01% · $86.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis. The primary endpoint was met with a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), with clinical remission of 33% and endoscopic improvement of 42%. Safety was consistent with the TL1A class with no drug-related serious adverse events. This de-risks SPY002 and supports the ongoing Part B randomized portion and combination arms.

Key Facts

  • Primary endpoint met: 10.7-point reduction in RHI from baseline at Week 12 (p<0.0001)
  • Clinical remission rate of 33% and endoscopic improvement rate of 42%
  • Change in modified Mayo Score of -3.7
  • Safety profile consistent with TL1A class; 2 SAEs deemed not drug-related, no drug-related SAEs, no deaths
  • Study population: 35% advanced therapy-exposed, mean disease duration 7.0 years, 56% baseline endoscopy score of 3
  • Company on track for SPY003 (anti-IL-23) Part A data in Q3 2026 and Part B enrollment underway

Financial Impact

No financial data in filing; positive clinical data likely increases probability of technical and regulatory success for SPY002, potentially enhancing partnership or valuation prospects for a $7B market cap biotech

Risk Factors

  • Open-label Part A design with no placebo control limits comparative interpretation
  • Small sample size (n=48) may not fully capture safety signals
  • Competitive landscape includes other anti-TL1A programs (e.g., duvakitug from Teva/Sanofi) with Phase 2b data
  • Part B randomized data expected later; failure to replicate would reverse gains

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001636282-26-000083
Exhibit: exhibit99120260615skyline-.htm0001636282-26-000083
Document: 0001636282-26-000083-index-headers.html0001636282-26-000083
Document: 0001636282-26-000083-index.html0001636282-26-000083
Document: 0001636282-26-000083.txt0001636282-26-000083

Track record

36 reports on SYRE

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026